Medical devices, healthcare technology and the business of care
510(k) clearance · K252885

OLYMPIC Posterior Spinal Fixation System; MASADA Modular Spinal Fixation System

Astura Medical · Decision date Jan 22, 2026

FDA DECISIONK252885

What did the FDA decide?

FDA records K252885 as a 510(k) premarket notification, with a decision dated Jan 22, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Orthopedic
Decision date
Jan 22, 2026

FDA source record

Regulatory record facts

Identifier
K252885
Regulatory pathway
510(k) premarket notification
Product code
PML
Decision code
SESE
Decision date
Jan 22, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Bone Cement, Posterior Screw Augmentation.

Product code
PML
FDA device class
2

FDA decision timeline

  1. K252885 received

    Application receipt date recorded by FDA.

  2. K252885 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code PML

Product / regulatory recordCompanyPathwayDecision dateSource
Spine Wave, Inc.510(k) clearanceJun 15, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Astura Medical

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Irving, TX

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records